Study | Anti-VEGF agent | Location of administration | Follow-up time (months) | Treatment group (n) | Events (% of total) | Complete success (% of total) | |||
Treatment | Control | Treatment | Control | Treatment | Control | ||||
Kahook, M.Y. | Ranibizumab (Lucentis) | Intravitreal | 6 | 5 | 5 | 0 (0%) | 0 (0%) | 100% | 100% |
Vanderwalle, E. et al | Bevacizumab (Avastin) | Intracameral | 12 | 32 | 34 | 8 (25%) | 16 (47%) | 75% (71%) | 53% (51%) |
Saeed, A.M. et al | Bevacizumab (Avastin) | Subconjunctival | 24 | 13 | 13 | 3 (23%) | 5 (38%) | 77% | 54% |
Kiddee, W. et al | Bevacizumab (Avastin) | Subconjunctival | 12 | 20 | 19 | 9 (45%) | 8 (42%) | 55% | 58% |
MMC, mitomycin-C; VEGF, vascular endothelial growth factor.